307 related articles for article (PubMed ID: 26686343)
1. Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.
Stone LA; Cutter GR; Fisher E; Richert N; McCartin J; Ohayon J; Bash C; McFarland H
J Neuroimaging; 2016 May; 26(3):296-302. PubMed ID: 26686343
[TBL] [Abstract][Full Text] [Related]
2. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis.
Liguori M; Meier DS; Hildenbrand P; Healy BC; Chitnis T; Baruch NF; Khoury SJ; Weiner HL; Bakshi R; Barkhof F; Guttmann CR
J Neurol Neurosurg Psychiatry; 2011 Oct; 82(10):1125-31. PubMed ID: 21429902
[TBL] [Abstract][Full Text] [Related]
3. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
4. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
5. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.
Minneboo A; Jasperse B; Barkhof F; Uitdehaag BM; Knol DL; de Groot V; Polman CH; Castelijns JA
J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):917-23. PubMed ID: 18077480
[TBL] [Abstract][Full Text] [Related]
6. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
9. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
10. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
[TBL] [Abstract][Full Text] [Related]
11. Thalamic damage and long-term progression of disability in multiple sclerosis.
Rocca MA; Mesaros S; Pagani E; Sormani MP; Comi G; Filippi M
Radiology; 2010 Nov; 257(2):463-9. PubMed ID: 20724544
[TBL] [Abstract][Full Text] [Related]
12. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort.
Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L
Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141
[TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
[TBL] [Abstract][Full Text] [Related]
14. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
15. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
16. [Current questions of multiple sclerosis: the secunder progressive form of the disease].
Vécsei L
Ideggyogy Sz; 2020 Jan; 73(1-2):7-14. PubMed ID: 32057199
[TBL] [Abstract][Full Text] [Related]
17. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
18. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis.
Giorgio A; Stromillo ML; Bartolozzi ML; Rossi F; Battaglini M; De Leucio A; Guidi L; Maritato P; Portaccio E; Sormani MP; Amato MP; De Stefano N
Mult Scler; 2014 Feb; 20(2):214-9. PubMed ID: 23877971
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
20. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
